REVB
Revelation Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.01
+0.00%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- -35.0%
- EBIT
- -39.0%
- EPS
- +74.5%
- Free cash flow
- +46.7%
- Operating cash flow
- +47.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +75.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- -13.8%
- EBIT
- -13.7%
- Net income
- +40.7%
- EPS
- +72.7%
- Free cash flow
- +54.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026